204 related articles for article (PubMed ID: 26581312)
1. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
Klimek L; Bousquet J; Price D
Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312
[TBL] [Abstract][Full Text] [Related]
2. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U
Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
[TBL] [Abstract][Full Text] [Related]
3. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
Meltzer EO; LaForce C; Ratner P; Price D; Ginsberg D; Carr W
Allergy Asthma Proc; 2012; 33(4):324-32. PubMed ID: 22856633
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
Derendorf H; Munzel U; Petzold U; Maus J; Mascher H; Hermann R; Bousquet J
Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study.
Klimek L; Bachert C; Mösges R; Munzel U; Price D; Virchow JC; Wahn U; Bousquet J
Allergy Asthma Proc; 2015; 36(1):40-7. PubMed ID: 25562555
[TBL] [Abstract][Full Text] [Related]
6. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
Berger WE; Shah S; Lieberman P; Hadley J; Price D; Munzel U; Bhatia S
J Allergy Clin Immunol Pract; 2014; 2(2):179-85. PubMed ID: 24607046
[TBL] [Abstract][Full Text] [Related]
7. MP29-02: a breakthrough for the treatment of allergic rhinitis.
Bernstein JA
Expert Opin Pharmacother; 2013 Oct; 14(15):2101-13. PubMed ID: 23977840
[TBL] [Abstract][Full Text] [Related]
8. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
[TBL] [Abstract][Full Text] [Related]
9. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
Carr W; Bernstein J; Lieberman P; Meltzer E; Bachert C; Price D; Munzel U; Bousquet J
J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
Meltzer E; Ratner P; Bachert C; Carr W; Berger W; Canonica GW; Hadley J; Lieberman P; Hampel FC; Mullol J; Munzel U; Price D; Scadding G; Virchow JC; Wahn U; Murray R; Bousquet J
Int Arch Allergy Immunol; 2013; 161(4):369-77. PubMed ID: 23652808
[TBL] [Abstract][Full Text] [Related]
11. Intranasal spray medications for maintenance therapy of allergic rhinitis.
Berger WE; Meltzer EO
Am J Rhinol Allergy; 2015; 29(4):273-82. PubMed ID: 26132312
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
Derendorf H; Meltzer EO; Hermann R; Canonica GW
Drugs Today (Barc); 2014 Jan; 50(1):15-31. PubMed ID: 24524103
[TBL] [Abstract][Full Text] [Related]
13. Azelastine and fluticasone nasal spray: any advantage?
Drug Ther Bull; 2014 Feb; 52(2):21-4. PubMed ID: 24504481
[TBL] [Abstract][Full Text] [Related]
14. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
Price D; Shah S; Bhatia S; Bachert C; Berger W; Bousquet J; Carr W; Hellings P; Munzel U; Scadding G; Lieberman P
J Investig Allergol Clin Immunol; 2013; 23(7):495-503. PubMed ID: 24654314
[TBL] [Abstract][Full Text] [Related]
15. MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety.
Berger WE
Expert Rev Clin Immunol; 2013 Sep; 9(9):803-11. PubMed ID: 24070043
[TBL] [Abstract][Full Text] [Related]
16. Escaping the trap of allergic rhinitis.
Rossi O; Massaro I; Caminati M; Quecchia C; Fassio F; Heffler E; Canonica GW
Clin Mol Allergy; 2015; 13(1):17. PubMed ID: 26244040
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.
Ratner PH; Hampel F; Van Bavel J; Amar NJ; Daftary P; Wheeler W; Sacks H
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):74-81. PubMed ID: 18254486
[TBL] [Abstract][Full Text] [Related]
18. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK.
Scadding G; Price D; El-Shanawany T; Ahmed S; Ray J; Sargur R; Kumar N
BMJ Open; 2017 Apr; 7(4):e014777. PubMed ID: 28442578
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device.
Hampel FC; Ratner PH; Van Bavel J; Amar NJ; Daftary P; Wheeler W; Sacks H
Ann Allergy Asthma Immunol; 2010 Aug; 105(2):168-73. PubMed ID: 20674829
[TBL] [Abstract][Full Text] [Related]
20. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review.
Klimek L; Berger WE; Bousquet J; Keith PK; Smith P; Sole D; Scadding G; Kuhl HC; Nguyen DT; Kopietz F; Koltun A
Int Arch Allergy Immunol; 2021; 182(11):1026-1035. PubMed ID: 34082425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
